RxDoctor Payments DataLook up a doctor →

Harris Tesher, MD

Pulmonary Disease · Englewood, NJNPI 1639338205

Payments from drug & device makers

$22,294in general payments, 2019–2025

Across 793 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • GSK$3K
  • AstraZeneca$3K
  • Mindray DS USA, Inc.$2K
  • Boehringer Ingelheim$833
  • Insmed, Inc.$810
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$2,07514%
  • Food & beverage$12,58085%
  • Education$1891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,294 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$237,274
Medicare patients
644
Services billed
2,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate21$409,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter533$405,018
Dupixent PenDupilumab15$54,938
Breo ElliptaFluticasone/Vilanterol105$48,149
Breztri AerosphereBudesonide/Glycopyr/Formoterol60$41,700
Pirfenidone11$30,908
EliquisApixaban12$17,124
Incruse ElliptaUmeclidinium Bromide38$15,922
Fluticasone-SalmeterolFluticasone Propion/Salmeterol96$13,246
TrulicityDulaglutide12$12,206
Albuterol Sulfate HfaAlbuterol Sulfate409$11,236
SymbicortBudesonide/Formoterol Fumarate24$6,856
Advair HfaFluticasone Propion/Salmeterol14$6,467
Fluticasone-VilanterolFluticasone/Vilanterol13$5,750
LivaloPitavastatin Calcium14$5,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$3,157$474,622688 claims
Boehringer IngelheimOfev$833$409,21621 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,738$48,55584 claims
PfizerEliquis$7,497$17,12412 claims
Lilly USA, LLCTrulicity$18$12,20612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →